Percutaneous Mitral Repair With the MitraClip System. Safety and Midterm Durability in the Initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) Cohort

Ted Feldman, Saibal Kar, Michael Rinaldi, Peter Fail, James Hermiller, Richard Smalling, Patrick L. Whitlow, William Gray, Reginald Low, Howard C. Herrmann, Scott Lim, Elyse Foster, Donald Glower

Research output: Contribution to journalArticle

612 Scopus citations

Abstract

Objectives: We undertook a prospective multicenter single-arm study to evaluate the feasibility, safety, and efficacy of the MitraClip system (Evalve Inc., Menlo Park, California). Background: Mitral valve repair for mitral regurgitation (MR) has been performed by the use of a surgically created double orifice. Percutaneous repair based on this surgical approach has been developed by use of the Evalve MitraClip device to secure the mitral leaflets. Methods: Patients with 3 to 4+ MR were selected in accordance with the American Heart Association/American College of Cardiology guidelines for intervention and a core echocardiographic laboratory. Results: A total of 107 patients were treated. Ten (9%) had a major adverse event, including 1 nonprocedural death. Freedom from clip embolization was 100%. Partial clip detachment occurred in 10 (9%) patients. Overall, 79 of 107 (74%) patients achieved acute procedural success, and 51 (64%) were discharged with MR of ≤1+. Thirty-two patients (30%) had mitral valve surgery during the 3.2 years after clip procedures. When repair was planned, 84% (21 of 25) were successful. Thus, surgical options were preserved. A total of 50 of 76 (66%) successfully treated patients were free from death, mitral valve surgery, or MR >2+ at 12 months (primary efficacy end point). Kaplan-Meier freedom from death was 95.9%, 94.0%, and 90.1%, and Kaplan-Meier freedom from surgery was 88.5%, 83.2%, and 76.3% at 1, 2, and 3 years, respectively. The 23 patients with functional MR had similar acute results and durability. Conclusions: Percutaneous repair with the MitraClip system can be accomplished with low rates of morbidity and mortality and with acute MR reduction to < 2+ in the majority of patients, and with sustained freedom from death, surgery, or recurrent MR in a substantial proportion (EVEREST I; NCT00209339. EVEREST II; NCT00209274).

Original languageEnglish (US)
Pages (from-to)686-694
Number of pages9
JournalJournal of the American College of Cardiology
Volume54
Issue number8
DOIs
StatePublished - Aug 18 2009

    Fingerprint

Keywords

  • mitral regurgitation
  • mitral repair
  • percutaneous valve therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Feldman, T., Kar, S., Rinaldi, M., Fail, P., Hermiller, J., Smalling, R., Whitlow, P. L., Gray, W., Low, R., Herrmann, H. C., Lim, S., Foster, E., & Glower, D. (2009). Percutaneous Mitral Repair With the MitraClip System. Safety and Midterm Durability in the Initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) Cohort. Journal of the American College of Cardiology, 54(8), 686-694. https://doi.org/10.1016/j.jacc.2009.03.077